US firm Arena Pharmaceuticals has initiated patient screening in a Phase I clinical trial of APD916, an oral drug that targets the histamine H3 receptor for the treatment of narcolepsy and cataplexy.

The randomised, double-blind, placebo-controlled Phase I trial will evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD916 and will enroll up to 72 healthy adult volunteers.

Narcolepsy is a chronic neurological disorder caused by the brain’s inability to regulate sleep-wake cycles normally, where patients experience irresistible bouts of sleep.

Cataplexy, or the sudden loss of voluntary muscle tone triggered by emotional factors, is a symptom of narcolepsy and can cause a range of physical changes, from slurred speech to complete weakness of most muscles.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData